Related references
Note: Only part of the references are listed.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes
Kristen S. Purrington et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
An analysis of FDA-approved drugs: natural products and their derivatives
Eric Patridge et al.
DRUG DISCOVERY TODAY (2016)
Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway
Huae Xu et al.
CANCER CELL INTERNATIONAL (2015)
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
Rute B. Marques et al.
EUROPEAN UROLOGY (2015)
Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States
Javaid Iqbal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
Valerie N. Barton et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines
Yuh Baba et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90
Su-Chan Lee et al.
MOLECULAR PHARMACOLOGY (2015)
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice
Martina Bonifazi et al.
BREAST (2014)
New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2014)
Triple-negative breast cancer: molecular subtypes and targeted therapy
Kim M. Hirshfield et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2014)
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Ines Vaz-Luis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
Ning Qing Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Adjuvant trastuzumab improves survival in early breast cancer
Vicki Brower
LANCET ONCOLOGY (2014)
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Abenaa M. Brewster et al.
LANCET ONCOLOGY (2014)
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
Angelo Gamez-Pozo et al.
PLOS ONE (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Molecular Heterogeneity of Triple-Negative Breast Cancer
Vandana G. Abramson et al.
CURRENT BREAST CANCER REPORTS (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Dawn R. Cochrane et al.
BREAST CANCER RESEARCH (2014)
Natural products: A continuing source of novel drug leads
Gordon M. Cragg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Ke-Da Yu et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity
Nicole L. Moore et al.
ENDOCRINE-RELATED CANCER (2012)
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2012)
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Higher Population-Based Incidence Rates of Triple-Negative Breast Cancer Among Young African-American Women Implications for Breast Cancer Screening Recommendations
Kathryn C. Amirikia et al.
CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
Ana Bosch et al.
CANCER TREATMENT REVIEWS (2010)
Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
Ramachandran Venkitaraman
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Natural product scaffolds as leads-to drugs
David J. Newman et al.
FUTURE MEDICINAL CHEMISTRY (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
Dezheng Huo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
What is triple-negative breast cancer?
William J. Irvin et al.
EUROPEAN JOURNAL OF CANCER (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Structural basis for depletion of heat shock protein 90 client proteins by deguelin
Seung Hyun Oh et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Bas Kreike et al.
BREAST CANCER RESEARCH (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
Jose Baselga et al.
ONCOLOGIST (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
7a-O-methyldeguelol, a modified rotenoid with an open ring-C, from the roots of Derris trifoloata
A Yenesew et al.
PHYTOCHEMISTRY (2005)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
